Iambic Therapeutics, Inc. IAM
Nov 10, 2026, 11:56 AM EST
- YTD
- -23.96%
- 1 year
- -23.96%
- Market cap
- 681.39M
- Revenue (ttm)
- 18.25M
- EPS (ttm)
- -2.69
- Shares out
- 47.40M
- YTD return
- -23.96%
- 1-year return
- -23.96%
- Volume
- 630.74K
- Avg volume
- 854.55K
- Open
- 14.47
- Previous close
- 13.38
- Day's range
- 12.80 – 15.00
- 52-week range
- 9.60 – 25.00
5D +1.25 (+9.13%)
Key statistics
- Enterprise value
- 637.77M
- PEG ratio
- 0.00
- Price / sales
- 61.84
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 224.70%
- Free cash flow
- 0
- Total cash
- 207.88M
- Total debt
- 5.23M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 18.91
- 200-day average
- 18.91
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- iambic.ai
News
Jefferies Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $35 
Iambic Therapeutics Jumps 17% After-Hours as Wall Street Turns Bullish on Its AI-Powered Drug Discovery Platform 
Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results 
12 Health Care Stocks Moving In Monday's Intraday Session 
CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday 
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
JP Morgan Initiates Coverage On Iambic Therapeutics with Overweight Rating, Announces Price Target of $22 
Citigroup Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $22 
B of A Securities Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $30 - Iambic Therapeutics Presents Updated Clinical Results From Its IAM1363 Inhibitor At ESMO Congress 2026
Your note
Sign in to keep a note on IAM — it syncs with the Stock Master app.